Fig. 4
Increased of circulating soluble PlGF, CCL3 and increase in specific T cells subsets during lead-in nintedanib monotherapy associated to clinical outcomes. A Plasma rate of Placental Growth Factor (PlGF) increased in patients without DCB between D-7 (13.4 pg/mL [range: 8.4–17.9]) and C1D1 (18.8 pg/mL [range: 10.8–30.3]) (Paired Wilcoxon signed rank test; p = 0.015). B Plasma rate of CCL3 were higher in patients with DCB (19.8 pg/mL [range: 11.7–26.1]) than without DCB (12.9 pg/mL [range: 9.9–17.8]) after 7 days of nintedanib monotherapy (non-parametric Wilcoxon rank sum test; p = 0.03). C Percentage of blood CCR4+ CXCR3+ T cells among effector memory CD4+ T cells and CD25high CD127low Tregs among total CD4+ T lymphocytes were higher at C1D1 in patients with DCB (25.3% [range: 21.2–35.8] and 10% [range: 6.4–15.4], respectively) than those without DCB (17.9% [range: 14.4–23.8] and 5.8% [range: 4.1–8.5], respectively) (non-parametric Wilcoxon rank sum test; p = 0.017 and p = 0.024, respectively). Abbreviations: PD = Progressive disease; SD = Stable disease; PR = Partial response; Ninte. = nintedanib; DCB = Durable clinical benefit; D-7 = day − 7; C1D1 = Cycle 1 day 1; MIP = Macrophage Inflammatory Protein